Novo Nordisk’s High-Dose Wegovy Approved by FDA to Boost Weight Loss Market Share

A higher dose of Novo Nordisk’s injectable obesity drug, Wegovy, has received U.S. Food and Drug Administration (FDA) approval, the company announced Thursday. This new formulation, Wegovy HD (semaglutide) injection 7.2 mg, demonstrated substantial weight loss in adults with obesity during clinical trials, offering a potential new option for individuals seeking more powerful weight management tools. The approval comes as Novo Nordisk navigates a shifting market landscape, where competition from Eli Lilly is increasing.

The FDA’s decision was expedited through a new voucher program established by Commissioner Marty Makary, designed to accelerate the review of drugs deemed national priorities. Novo Nordisk obtained this voucher as part of an agreement reached with the Trump administration late last year, linked to efforts to lower the prices of its obesity medications in specific contexts. Details of that agreement were reported by STAT News in November 2025.

Understanding Wegovy HD: Trial Results and Efficacy

The approval of Wegovy HD is based on data from the STEP UP trial program, specifically a 72-week study evaluating the efficacy and safety of the 7.2 mg dose. Results showed that adults with obesity who received Wegovy HD experienced an average weight loss of approximately 21% when adhering to the treatment plan. Even among participants who didn’t remain on the treatment for the full 72 weeks, the average weight loss remained significant, at around 19%. Notably, about one in three trial participants taking Wegovy HD achieved a weight loss of 25% or higher. These findings were released by Novo Nordisk on March 19, 2026.

Semaglutide, the active ingredient in Wegovy and Wegovy HD, is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1s work by mimicking a natural hormone in the body that regulates appetite and food intake. They can help people feel fuller for longer, leading to reduced calorie consumption. Wegovy HD is intended for use alongside a reduced-calorie diet and increased physical activity. It’s key to note that patients must have tolerated a 2.4 mg dosage of Wegovy for at least four weeks before being considered for the higher dose, and additional weight reduction must be clinically indicated.

Expanding the Wegovy Portfolio and Competitive Landscape

This approval expands the Wegovy label, which already includes multiple formulations, including a Wegovy pill, and indications not available with other GLP-1 weight loss medications. Jamey Millar, executive vice president of US Operations at Novo Nordisk, stated that “no other weight loss medicine has been studied to show superiority to Wegovy HD.” However, the company has faced increasing competition from Eli Lilly in the weight loss market. STAT News reported in June 2025 that Novo Nordisk’s dominance in the weight loss drug market had begun to slip as Eli Lilly gained ground.

Beyond weight loss, Wegovy has also been proven to reduce the risk of cardiovascular events – stroke, heart attack, or cardiovascular death – in adults with obesity and existing heart disease. This distinction sets Wegovy apart from other GLP-1 medications for weight loss. The broader clinical profile of Wegovy, encompassing multiple indications, is a key differentiator for Novo Nordisk.

Safety Considerations and What the Label Says

As with any medication, safety is paramount. The FDA label for Wegovy includes information on potential side effects, and contraindications. Available data from clinical trials and pharmacovigilance monitoring do not currently establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, according to information available in the FDA’s official label (PDF). However, this does not preclude the possibility of such risks, and further research is ongoing.

Common side effects associated with Wegovy and other GLP-1 receptor agonists can include nausea, vomiting, diarrhea, and constipation. These side effects are generally mild to moderate and tend to subside over time. It is crucial for patients to discuss any concerns or side effects with their healthcare provider.

The Voucher Program and Regulatory Speed

The use of the FDA’s National Priority Voucher program significantly accelerated the review process for Wegovy HD. Novo Nordisk is expected to receive a decision from the FDA on its 25 mg oral semaglutide (referred to as “Wegovy in a pill”) around the same time, further expanding its weight management options. Fierce Pharma reported in November 2025 that the voucher could expedite the FDA’s decision to within one to two months.

What Comes Next: Monitoring and Further Research

Following the approval of Wegovy HD, ongoing monitoring of its real-world effectiveness and safety will be crucial. The FDA will continue to review data from post-market surveillance to identify any previously unknown risks or benefits. Further research may also be conducted to explore the long-term effects of Wegovy HD and to identify which patients are most likely to benefit from the higher dose. Healthcare providers will play a vital role in assessing individual patient needs and determining whether Wegovy HD is an appropriate treatment option, always in conjunction with lifestyle modifications.